# MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC

> **NCT07235566** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 60 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** MRG003 in combination with pucotenlimab

## Key facts

- **NCT ID:** NCT07235566
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2029-04
- **Final completion:** 2031-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07235566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07235566, "MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07235566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*